NEW YORK, March 14, 2018 /PRNewswire/ --
NetworkNewsWire Editorial Coverage
As the legal cannabismarket continues to grow, new deals are creating opportunities for a range of companies and an influx of investments. PreveCeutical Medical, Inc. (CSE: PREV) (OTC: PRVCF) (FSE: 18H) (PRVCF Profile) has teamed
Cannabis Plant Material in Medical Research PreveCeutical's work extends to one of the most exciting and fastest growing areas of medical research - the use of cannabidiols (CBDs). PreveCeutical and Aurora Cannabis (OTCQX: ACBFF) (TSX: ACB) recently announced the grant of three permits by the Australian Department of Health for the import of CBDs for research purposes (http://nnw.fm/K2l88). The CBD will go to PACE at the University of Queensland, where it will be used in a research program led by Dr. Parekh. This program will be built around PreveCeutical's sol-gel nasal drug delivery system. The aim is to develop sol-gels that deliver CBDs - active, non-psychotropic ingredients from cannabis - more effectively into the patient's system. CBDs can provide valuable solutions for a wide range of symptoms including pain, inflammation, seizures and neurological disorders. The research team's hope is that, through a more direct nose-to-brain delivery system, they can provide faster, more effective relief using a time-release, nano bubble technology. Notably, the cannabis will be provided by Aurora Cannabis. A licensed producer under the Canadian government's medical cannabis regulations, Aurora has over 175,000 square feet of production facilities. These allow it to provide large volumes of high-grade medical cannabis for customers such as PreveCeutical. Better Ways to Deliver Medicine
The sol-gel delivery system is one of the most exciting developments to come out of PreveCeutical's medical research program. It provides medicine in a liquid form that is squirted up the nose. There, it forms a gel that slowly and steadily releases the active ingredients over time. Sol-gel gets around barriers within the body that limit the effectiveness of drugs targeting the brain. Traditional delivery methods, including pills and injections, go through a complex range of bodily systems before reaching the target. The liver filters out and metabolizes ingredients, affecting both effectiveness and delivery time. The blood-brain barrier blocks the path for active ingredients to reach the brain. Sol-gel uses hydrogels-molecules that soak up biological fluids and closely resemble living tissue. Sprayed onto the nasal mucosa, the medicine has a more direct route to the brain, bypassing bodily barriers and increasing the effectiveness of the treatment. The gel's controlled release of medicine means that delivery is steady as well as direct, reducing daily doses to once or twice a week with a 90 percent bioavailability. Supplying a Growing Research Business ABcann Global (TSX-V: ABCN) (OTCQB: ABCCF) is another company gaining traction in its cannabis business. The company runs a production facility in Ontario with 14,500 square feet of growing space. Its computer-controlled environment uses proprietary lighting systems designed to replicate the natural environment and provide a perfect space for cannabis to grow. ABcann also owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to 1 million square feet, and is pursuing ongoing global expansion into the European, Australian and Israeli markets.
Canadian companies are using their experience and favorable market conditions to expand into other cannabis markets. Aphria (TSX: APH) (OTCQB: APHQF), a Canadian medical cannabis company, is working in not only the Canadian but also the American market. Its strategy of collaboration and targeted investment has led to significant expansion. This includes a recent agreement with the Société des alcools du Québec (SAQ) to supply high-quality cannabis products through retail outlets in Quebec and an associated e-commerce platform. Canopy Growth (TSX: WEED) (OTC: TWMJF) has achieved an even bigger team-up through an agreement with Constellation Brands. The $42 billion company is behind the Corona, Modelo and Svedka brands and has taken a $191 million stake in Canopy Growth, providing investment for the development of cannabis-related soft drinks. Canopy Growth's other collaborations include a deal with Sunniva, a vertically integrated cannabis company focused on the Canadian and Californian markets. This deal will see a steady supply of cannabis for Canopy Growth, allowing it to expand its share of the market. Research is leading the way in the cannabis market, with the development of new drugs and recreational products. That research is powering fresh growth on the production side for a sector that's healthier than ever before. For more information on PreveCeutical Medical Inc., visit PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H).
Corporate Communications Contact: NetworkNewsWire (NNW) New York +1-212-418-1217 Office Editor@NetworkNewsWire.com Media Contact: FN Media Group, LLC NNW@FinancialNewsMedia.com +1-(954)345-0611
Subscribe to our Free Newsletters!
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...